title: [Human immunoglobulins, adverse drug reaction, prevention].
abstract: OBJECTIVE
  Adverse drug reactions occur during 10% of immunoglobulin treatment. Risk factor of adverse drug reactions have been identified.
  Simple measures during prescription, administration and supervision of immunoglobulin treatment should prevent most of serious and non-serious adverse drug reactions. Patients with risk factor of adverse drug reactions may be identified. Hydration before and during immunoglobulin treatment is recommended. Low dose of immunoglobulin and slow rate of infusion associated with hydration should prevent many adverse drug reactions. Anyway follow-up of tolerance during infusion is necessary. Changing immunoglobulin preparation does not prevent adverse drug reactions although measures of safe prescription and administration do.
  
  
  CONCLUSIONS
  Careful prescription, administration and supervision of immunoglobulin therapy should prevent most of immunoglobulin-related adverse drug reactions.
authors.affiliation: Service de médecine interne, Pôle médecine-urgences, Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, 1 rue J. Burguet 33075 Bordeaux cedex, France. marike.delacre@chu-bordeaux.fr
authors.forename: M
authors.initials: M
authors.lastname: Grenouillet-Delacrea
authors.forename: M
authors.initials: M
authors.lastname: Longy-Boursier
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000517:prevention & control; D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control; D011307:Drug Prescriptions; D005440:Fluid Therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects*; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects*; D008991:Monitoring, Physiologic; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors